A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

导出 OA

翻译打印收藏纠错

作者： Antonio,Jimeno ^[1] ; Julie E,Bauman ^[2] ; Charles,Weissman ^[3] ; Douglas,Adkins ^[4] ; Ian,Schnadig ^[5] ; Patrice,Beauregard ^[6] ; Daniel W,Bowles ^[7] ; Alexander,Spira ^[8] ; Benjamin,Levy ^[9] ; Nagashree,Seetharamu ^[10] ; Diana,Hausman ^[11] ; Luke,Walker ^[11] ; Charles M,Rudin ^[12] ; Keisuke,Shirai ^[13]

作者单位： University of Colorado School of Medicine, Aurora, CO, United States. Electronic address: antonio.jimeno@ucdenver.edu. ^[1] University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States. ^[2] New York Hematology, New York, NY, United States. ^[3] Washington University, St. Louis, MO, United States. ^[4] Compass Oncology, Tualatin, OR, United States; US Oncology Research, The Woodlands, TX, United States. ^[5] CHUS Hôpital Fleurimont, Quebec, Canada. ^[6] University of Colorado School of Medicine, Aurora, CO, United States; Denver Veterans Affairs Medical Center, Denver, CO, United States. ^[7] Virginia Cancer Specialists, Fairfax, VA, United States; US Oncology Research, The Woodlands, TX, United States. ^[8] Beth Israel Hospital, St. Luke's Hospital, Mount Sinai Health System, New York, NY, United States. ^[9] New York University, New York, NY, United States. ^[10] Oncothyreon Inc., Seattle, WA, United States. ^[11] Johns Hopkins University, Baltimore, MD, United States. ^[12] Medical University of South Carolina, Charleston, SC, United States. ^[13]

关键词 Docetaxel Head and neck squamous cell cancer PI3K PIK3CA